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Figure S1. Transduction efficacy of CAR constructs. (A) Mouse splenocytes derived from 
ChRLuc/OT-1/Rag-/- mice were transduced with retroviruses encoding L1CAM-specific SS-4-
1BB/ζ, LS-4-1BB/ζ, SS-28/ζ or LS-28/ζ CARs. Cells were stained with cetuximab (anti-EGFR anti-
body) and anti-CD8 antibody to assess transduction efficacy by flow cytometry. Untransduced 
CD8+ T cells served as negative control. (B) Representative flow cytometry plots showing CD8 and 
EGFRt expression on CD8+ human T cells transduced with L1CAM-specific SS-4-1BB/ζ, LS-4-
1BB/ζ, SS-28/ζ or LS-28/ζ constructs after MACS enrichment. Untransduced T cells served as nega-
tive control. (C) Mouse splenocytes derived from ChRLuc/OT-1/Rag-/- mice were transduced with 
retroviruses encoding HER2-SS-4-1BB/ζ, HER2-LS-4-1BB/ζ, HER2-SS-28/ζ or HER2-LS-28/ζ CARs 
and stained with cetuximab (anti-EGFR antibody) and anti-CD8 antibody to determine transduc-
tion efficacy by flow cytometry. 
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Figure S2. Target antigen surface expression on tumor cells. Flow cytometry analysis of L1CAM 
expression on SK-N-BE(2) neuroblastoma cells (A) and single cells prepared from a PDX stained 
with anti-L1CAM monoclonal antibody (B). (C) Flow cytometry analysis of HER2 expression on 
SKOV3 ovarian carcinoma cells stained with anti-HER2 antibody. Cells stained with the isotype 
control antibody served as control. 
 
Figure S3. Flow cytometry gating strategy to identify T cells within co-cultures with tumors cells. 
Single cell suspension was stained with anti-GD2 (to discriminate from GD2+ tumor cells), anti-
CD8 and annexin V conjugated with different fluorochromes and analyzed by flow cytometry. 
Among single cells, T cells (CD8+, GD2-) were selected to assess annexin V positivity. 




Figure S4. PDX mouse model treated with single dose of 1x106 human L1CAM-specific CAR T 
cells. NOG mice were engrafted with a neuroblastoma PDX and treated 40 days later with a single 
dose of 1x106 human L1CAM-SS-28/ζ (n=5), L1CAM-SS-28/ζ (n=5) or untransduced T cells (n=5). 
